Relebactam
- Generic Name
- Relebactam
- Brand Names
- Recarbrio
- Drug Type
- Small Molecule
- Chemical Formula
- C12H20N4O6S
- CAS Number
- 1174018-99-5
- Unique Ingredient Identifier
- 1OQF7TT3PF
- Background
Relebactam is a diazabicyclooctane beta-lactamase inhibitor, similar in structure to avibactam. It includes a piperidine ring which reduces export from bacterial cells by producing a positive charge. It is currently available in a combination product which includes imipenem and cilastatin to treat complicated urinary tract infections (UTIs), pyelonephritis, and complicated intra-abdominal infections in adults. It is considered to be a last-line treatment option and gained FDA approval as part of the combination product RecarbrioⓇ in July 2019.
- Indication
Relebactam is indicated in combination with imipenem and cilastatin for the treatment of complicated urinary tract infections (including pyelonephritis), and complicated intra-abdominal infections caused by susceptible organisms in adults.
- Associated Conditions
- Complicated Intra-Abdominal Infections (cIAIs), Complicated Urinary Tract Infection, Pyelonephritis
In Vitro Activity of Ceftolozane/Tazobactam and Imipenem/Relebactam in Clinical Isolates of Pseudomonas Aeruginosa and Enterobacterales Collected From Hematology and Oncology Patients
- Conditions
- Ceftolozane/TazobactamImipenem/RelebactamHematology and Oncology
- Interventions
- First Posted Date
- 2019-12-12
- Last Posted Date
- 2019-12-12
- Lead Sponsor
- Emilio Bouza
- Target Recruit Count
- 1005
- Registration Number
- NCT04196608
- Locations
- 🇪🇸
HG Gregorio Marañón, Madrid, Spain
Imipenem/Relebactam/Cilastatin Versus Piperacillin/Tazobactam for Treatment of Participants With Bacterial Pneumonia (MK-7655A-014)
- Conditions
- Bacterial Pneumonia
- Interventions
- First Posted Date
- 2015-07-09
- Last Posted Date
- 2020-04-16
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 537
- Registration Number
- NCT02493764
Study of the Safety, Tolerability, and Efficacy of Relebactam (MK-7655) + Imipenem/Cilastatin Versus Imipenem/Cilastatin Alone to Treat Complicated Intra-Abdominal Infection [cIAI] (MK-7655-004)
- Conditions
- Intra-abdominal Infections
- Interventions
- Drug: Imipenem/cilastatin
- First Posted Date
- 2012-01-09
- Last Posted Date
- 2019-06-10
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 351
- Registration Number
- NCT01506271
Safety, Tolerability, and Efficacy of MK-7655 (Relebactam) + Imipenem/Cilastatin Versus Imipenem/Cilastatin Alone for Treating Complicated Urinary Tract Infection (cUTI) (MK-7655-003)
- Conditions
- Urinary Tract InfectionsPyelonephritis
- Interventions
- Drug: imipenem/cilastatin 500 mg
- First Posted Date
- 2012-01-06
- Last Posted Date
- 2019-05-24
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 302
- Registration Number
- NCT01505634
A Single-Dose Study to Investigate the Pharmacokinetics of MK-7655 in Participants With Impaired Renal Function (MK-7655-005)
- Conditions
- Infectious Disease
- Interventions
- First Posted Date
- 2011-01-12
- Last Posted Date
- 2020-06-11
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 49
- Registration Number
- NCT01275170
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.